drugset / Trial / NCT03997279
Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii
RandomizedParallel-groupTriple-blindTreatment
Summary
This study assesses the effect of quadruple therapy for H. pylori, with the addition of probiotics Saccharomyces boulardii. In addition, he assesses whether this combination reduces the frequency of adverse effects of eradication therapy, and whether it affects the compliance.
Timeline
- Start
- 2019-06
- Primary completion
- 2020-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saccharomyces boulardii | Other / unclassified | 500 mg | — |
| Background | Amoxicillin | Other / unclassified | 1000 mg | — |
| Background | Clarithromycin | Small molecule | 500 mg | — |
| Background | Metronidazole | Small molecule | 500 mg | — |
| Background | Rabeprazole | Small molecule | 20 mg | — |